drugset / Trial / NCT06634394
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
NaSingle-groupOpen-labelTreatment
Summary
A multi-center, open-label, dose-finding study of five dose levels of APVO436 in combination with venetoclax and azacitidine (ven/aza) in adult patients with newly diagnosed, CD123+ AML.
Timeline
- Start
- 2024-10-01
- Primary completion
- 2027-10
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APVO436 | Monoclonal antibody | — | Intravenous |
| Background | Azacitidine | Other / unclassified | — | Intravenous |
| Background | Venetoclax | Small molecule | — | Oral |